{"id":"NCT02949128","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)","officialTitle":"Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01-11","primaryCompletion":"2023-01-24","completion":"2023-01-24","firstPosted":"2016-10-31","resultsPosted":"2020-02-10","lastUpdate":"2024-02-20"},"enrollment":58,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atypical Hemolytic Uremic Syndrome (aHUS)"],"interventions":[{"type":"BIOLOGICAL","name":"Ravulizumab","otherNames":["ALXN1210","Ultomiris"]}],"arms":[{"label":"Ravulizumab","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to assess the safety and efficacy of ravulizumab to control disease activity in adolescent and adult participants with aHUS who had not previously used a complement inhibitor.","primaryOutcome":{"measure":"Percentage Of Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26","timeFrame":"Week 26","effectByArm":[{"arm":"Ravulizumab","deltaMin":53.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":37,"countries":["United States","Australia","Austria","Belgium","Canada","France","Germany","Italy","Japan","Russia","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["34169200","39468592","36329366","33783815","33407224"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":58},"commonTop":["Headache","Diarrhoea","Vomiting","Nausea","Arthralgia"]}}